Table 1.
MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, SHMT1 1420C>T, TS 1494del6, and TS 28-bp repeat genotype frequencies, ORs and 95% CIs in acute leukemia cases and controls
| Controls n | ALL |
AML |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Total ALL |
B-lineage |
T-lineage |
|||||||
| n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | ||
| Total* | 824 | 939 | 765 | 87 | 89 | ||||
| MTHFR (677 C>T) | |||||||||
| CC | 359 (47.2) | 374 (46.4) | 1.00 | 302 (46.0) | 1.00 | 37 (50.7) | 1.00 | 47 (59.5) | 1.00 |
| CT | 317 (41.7) | 341 (42.4) | 1.03 (0.84-1.27) | 275 (41.8) | 1.03 (0.83-1.29) | 29 (39.7) | 0.89 (0.53-1.48) | 21 (26.6) | 0.51 (0.30-0.87) |
| TT | 84 (11.1) | 90 (11.2) | 1.03 (0.74-1.43) | 80 (12.2) | 1.13 (0.80-1.59) | 7 (9.6) | 0.81 (0.35-1.88) | 11 (13.9) | 1.00 (0.50-2.01) |
| CC versus CT/TT | 401 (52.8) | 431 (53.6) | 1.03 (0.85-1.26) | 355 (54.0) | 1.05 (0.85-1.30) | 36 (49.3) | 0.87 (0.54-1.41) | 32 (40.5) | 0.61 (0.38-0.98) |
| MTHFR (1298A>C) | |||||||||
| AA | 350 (46.1) | 408 (51.9) | 1.00 | 343 (53.2) | 1.00 | 33 (48.5) | 1.00 | 41 (52.6) | 1.00 |
| AC | 332 (43.7) | 305 (38.8) | 0.79 (0.64-0.97)a | 243 (37.7) | 0.75 (0.60-0.93)b | 32 (47.1) | 1.02 (0.61-1.70) | 26 (33.3) | 0.67 (0.40-1.12) |
| CC | 77 (10.2) | 73 (9.3) | 0.81 (0.57-1.15) | 59 (9.1) | 0.78 (0.54-1.13) | 3 (4.4) | 0.41 (0.12-1.38) | 11 (14.1) | 1.22 (0.60-2.48) |
| AA versus AC/CC | 409 (53.9) | 378 (48.1) | 0.79 (0.65-0.97)c | 302 (46.8) | 0.75 (0.61-0.93)d | 35 (51.5) | 0.91 (0.55-1.49) | 37 (47.4) | 0.77 (0.48-1.23) |
| SHMT1 (1420C>T) | |||||||||
| CC | 351 (46.1) | 401 (49.0) | 1.00 | 330 (49.0) | 1.00 | 35 (47.9) | 1.00 | 41 (52.6) | 1.00 |
| CT | 318 (41.8) | 320 (39.1) | 0.88 (0.71-1.09) | 259 (38.5) | 0.87 (0.69-1.08) | 33 (45.2) | 1.04 (0.63-1.71) | 28 (35.9) | 0.75 (0.46-1.25) |
| TT | 92 (12.1) | 97 (11.9) | 0.92 (0.67-1.27) | 84 (12.5) | 0.97 (0.70-1.35) | 5 (6.9) | 0.55 (0.21-1.43) | 9 (11.5) | 0.84 (0.39-1.79) |
| CC versus CT/TT | 410 (53.9) | 417 (51.0) | 0.89 (0.73-1.09) | 343 (51.0) | 0.89 (0.72-1.10) | 38 (52.1) | 0.93 (0.57-1.50) | 37 (47.4) | 0.77 (0.48-1.23) |
| TS 28bp repeat† | |||||||||
| 2R/2R | 181 (24.0) | 193 (25.4) | 1.00 | 165 (26.6) | 1.00 | 13 (18.1) | 1.00 | 15 (18.5) | 1.00 |
| 2R/3R | 368 (48.8) | 344 (45.3) | 0.88 (0.68-1.13) | 274 (44.2) | 0.82 (0.63-1.06) | 33 (45.8) | 1.25 (0.64-2.43) | 40 (49.4) | 1.31 (0.71-2.44) |
| 3R/3R | 205 (27.2) | 222 (29.3) | 1.02 (0.77-1.34) | 181 (29.2) | 0.97 (0.72-1.30) | 26 (36.1) | 1.77 (0.88-3.54) | 26 (32.1) | 1.53 (0.79-2.98) |
| 2R2R versus others | 575 (76.0) | 570 (74.6) | 0.93 (0.74-1.17) | 457 (73.4) | 0.87 (0.68-1.11) | 59 (81.9) | 1.43 (0.77-2.66) | 66 (81.5) | 1.38 (0.77-2.49) |
| TS (1494 del6) | |||||||||
| 6-bp+/6-bp+ | 373 (49.0) | 423 (49.5) | 1.00 | 353 (50.4) | 1.00 | 36 (46.8) | 1.00 | 41 (48.8) | 1.00 |
| 6-bp+/6-bp− | 331 (43.4) | 336 (39.3) | 0.90 (0.73-1.10) | 268 (38.3) | 0.86 (0.69-1.06) | 32 (41.6) | 1.00 (0.61-1.65) | 30 (35.7) | 0.82 (0.5-1.35) |
| 6-bp−/6-bp− | 58 (7.6) | 96 (11.2) | 1.46 (1.02-2.08)e | 79 (11.3) | 1.44 (1.00-2.08)f | 9 (11.7) | 1.61 (0.74-3.51) | 13 (15.5) | 2.04 (1.03-4.03)g |
| 6-bp+/6-bp+ versus 6-bp+/6-bp−/6-bp−/6-bp− | 389 (51.0) | 432 (50.5) | 0.98 (0.81-1.19) | 347 (49.6) | 0.94 (0.77-1.16) | 41 (53.2) | 1.09 (0.68-1.75) | 43 (51.2) | 1.02 (0.64-1.58) |
| MTR 2756 (A>G) | |||||||||
| AA | 510 (67.2) | 531 (61.0) | 1.00 | 431 (60.6) | 1.00 | 48 (61.6) | 1.00 | 43 (55.8) | 1.00 |
| AG | 223 (29.4) | 288 (33.1) | 1.24 (1.00-1.53)h | 240 (33.8) | 1.27 (1.02-1.59)i | 26 (33.3) | 1.24 (0.75-2.05) | 28 (36.4) | 1.49 (0.90-2.46) |
| GG | 26 (3.4) | 51 (5.9) | 1.88 (1.16-3.07)j | 40 (5.6) | 1.82 (1.09-3.03)k | 4 (5.1) | 1.63 (0.55-4.88) | 6 (7.8) | 2.74 (1.07-7.01)l |
| AA versus AG/GG | 249 (32.8) | 339 (39.0) | 1.31 (1.07-1.60)m | 280 (39.4) | 1.33 (1.07-1.65)n | 30 (38.4) | 1.28 (0.79-2.07) | 34 (44.2) | 1.62 (1.01-2.60)o |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; and OR, odds ratio.
*
Total includes persons for whom a result was not available, and varied between single nucleotide polymorphisms.
†
Includes 2 cases with 1R/1R, one case with 2R/4R, and one case with 3R/4R, and 2 controls with 3R/4R genotypes.
aP = .03, bP = .01, cP = .02, dP = .01, eP = .03, fP = .05, gP = .04, hP = .05, iP = .03, jP = .01, kP = .02, lP = .04, mP = .01, nP = .01, oP = .05.